Citius Pharmaceuticals financials
$0.5545+1.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Jun 30 | Q2 '26 Mar 31 | Q1 '26 Dec 31 | Q4 '25 Sep 30 | Q3 '25 Jun 30 | Q2 '25 Mar 31 | Q1 '25 Dec 31 | Q4 '24 Sep 30 | Q3 '24 Jun 30 | Q2 '24 Mar 31 | Q1 '24 Dec 31 | Q4 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | $3.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $1.0M | $1.3M | $3.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 67.1% | 80.3% | 80.0% | — | — | — | — | — | — | — | — | — |
| Operating income | -$11.7M | -$32.2M | -$9.0M | -$8.4M | -$8.8M | -$11.3M | -$10.0M | -$11.1M | -$10.6M | -$11.0M | -$9.3M | -$10.1M |
| Net income | -$8.9M | -$21.2M | -$8.2M | -$8.0M | -$8.8M | -$10.9M | -$9.8M | -$11.5M | -$10.9M | -$8.5M | -$9.2M | -$11.1M |
| Net margin | −593.3% | −1273.4% | −208.4% | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.34 | $-0.95 | $-0.38 | $-0.46 | $-0.80 | $-1.27 | $-1.30 | $-1.59 | $-1.57 | $-1.34 | $-1.45 | $-1.75 |
| EBITDA | -$11.7M | -$32.2M | -$9.0M | -$8.4M | -$8.8M | -$11.3M | -$10.0M | -$11.1M | -$10.6M | -$11.0M | -$9.3M | -$10.1M |
| Operating cash flow | -$8.7M | -$1.3M | -$13.0M | -$11.9M | -$5.4M | -$4.5M | -$4.7M | -$5.9M | -$8.4M | -$7.8M | -$6.1M | -$6.8M |
| Free cash flow | -$8.7M | -$1.3M | -$13.0M | -$11.9M | -$5.4M | -$4.5M | -$4.7M | -$5.9M | -$8.4M | -$7.8M | -$6.1M | -$6.8M |
| Diluted shares | 26.2M | 22.4M | 21.5M | 17.2M | 11.0M | 8.6M | 7.5M | 7.2M | 7.0M | 6.4M | 6.4M | 6.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.0M | $4.6M | $7.7M | $4.3M | $6.1M | $26.4K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $6.4M | $0.00 | $1.0M | $1.0M | $1.0M | $0.00 |
| Total assets | $142.3M | $132.5M | $140.4M | $130.9M | $127.7M | $121.5M |
| Total liabilities | $66.3M | $63.5M | $46.9M | $53.4M | $60.1M | $57.9M |
| Shareholders' equity | $75.9M | $69.1M | $93.5M | $77.5M | $67.6M | $63.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology